EGFR and Miyoshi myopathy: Though it was reported that first/second generation EGFR-TKIs (Gefitinib/Afatinib) exhibit moderate or no inhibition in NRAS wildtype or mutant MM cells (LP-1 and L-363, respectively) within the EGFR signaling pathway [21], inadvertently, we found that the FHND004 from modifying the third-generation EGFR-TKI AZD9291 (Osimertinib) might have a satisfactory antitumor effect in MM cells (ARP1 and H929).